Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 10 Saturday Friday Sunday Monday Tuesday Publication Only SUNDAY, JUNE 2 ND 9:00am - 1:00pm Central Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:00am - 12:00pm Hall A Poster 1025 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03 Hamilton E Hamilton E Breast Cancer— Metastatic 9:00am - 12:00pm Hall A Poster 5046 Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Secondary analysis of the SPARTAN trial. Roy S Chowdhury S Genitourinary Cancer— Prostate, Testicular, and Penile 9:00am - 12:00pm Hall A Poster 1056 BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC). Juric D Patel M, Moore K Breast Cancer - Metastatic 9:00am - 12:00pm Hall A Poster 1091 Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple- negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results. Seneviratne L Danso M, O'Shaughnessy J, Patt D, Mardones M Breast Cancer - Metastatic 9:00am - 12:00pm Hall A Poster TPS1123 ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd). Tripathy D Ali K, Danso M, Yardley D, Andersen J, O'Shaughnessy J Breast Cancer - Metastatic 9:00am - 12:00pm Hall A Poster TPS4607 FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors. Hanna G Patel M, Henry J Genitourinary Cancer— Kidney and Bladder 9:00am - 12:00pm Hall A Poster TPS4619 A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2. Loriot Y Garmezy B Genitourinary Cancer— Kidney and Bladder 9:00am - 12:00pm Hall A Poster TPS1128 First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer Saura C Perez C, Hamilton E, Henry J Breast Cancer— Metastatic 9:45 - 11:15am Hall D1 Oral Chair Hamilton E Next-Generation Antibody-Drug Conjugates: The Revolution Continues 9:45 - 11:15am 9:45 - 9:57am Hall D1 Oral The ABCs of ADCs: What Does the Future Hold? Hamilton E Next-Generation Antibody-Drug Conjugates: The Revolution Continues